HighTower Advisors LLC has reduced its stake in Abbott Laboratories, selling 35,569 shares, which now leaves them with 1,838,381 shares valued at approximately $246.2 million. Despite recent price target cuts from some brokerages, Abbott currently holds a consensus “Moderate Buy” rating with an average target price of $137.05. The company recently reported Q4 EPS of $1.50, revenue of $11.46 billion, set FY2026 guidance, and increased its quarterly dividend to $0.63.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
HighTower Advisors LLC Sells 35,569 Shares of Abbott Laboratories $ABT
HighTower Advisors LLC has reduced its stake in Abbott Laboratories, selling 35,569 shares, which now leaves them with 1,838,381 shares valued at approximately $246.2 million. Despite recent price target cuts from some brokerages, Abbott currently holds a consensus “Moderate Buy” rating with an average target price of $137.05. The company recently reported Q4 EPS of $1.50, revenue of $11.46 billion, set FY2026 guidance, and increased its quarterly dividend to $0.63.